Published in

Portland Press, Biochemical Society Transactions, 2(42), p. 587-592, 2014

DOI: 10.1042/bst20130229

Links

Tools

Export citation

Search in Google Scholar

From epidemiology to pathophysiology: what about caffeine in Alzheimer’s disease?

Journal article published in 2014 by Vanessa Flaten, Cyril Laurent, Joana E. Coelho ORCID, Ursula Sandau, Vânia L. Batalha, Sylvie Burnouf, Malika Hamdane, Sandrine Humez, Detlev Boison, Luísa V. Lopes, Luc Buée ORCID, David Blum, Luc Buee
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

AD (Alzheimer's disease) is the most prevalent form of dementia in the aged population. Definitive diagnosis of AD is based on the presence of senile plaques and neurofibrillary tangles that are identified in post-mortem brain specimens. A third pathological component is inflammation. AD results from multiple genetic and environmental risk factors. Among other factors, epidemiological studies report beneficial effects of caffeine, a non-selective antagonist of adenosine receptors. In the present review, we discuss the impact of caffeine and the adenosinergic system in AD pathology as well as consequences in terms of pathology and therapeutics.